Bausch Health Ireland Limited

Dow Pharmaceutical Sciences, Inc.

Allergan, Inc.

Almirall, LLC

Valeant Pharmaceuticals North America

Bausch Health Us, LLC

Varsha D Bhatt

Radhakrishnan Pillai

Gordon J Dow

Arturo Angel

Kevin S Warner

Ajay P Parashar

Nayan Desai

Vijaya Swaminathan

Yunik Chang

Pramod P Sarpotdar

Sarmistha Basu

The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.

Topical compositions

The present invention provides compositions containing efinaconazole, butylated hydroxytoluene, a salt of ethylenediaminetetraacetic acid, and optional citric acid. The compositions exhibit stable color profiles and are useful in the treatment of fungal infections.

Stabilized efinaconazole compositions as antifungals

Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same.

Topical compositions and methods for treating psoriasis

Topical pharmaceutical compositions for treating a skin condition or disorder are provided. The topical pharmaceutical compositions can be formulated as lotions containing a therapeutically effective amount of an active agent, such as tretinoin, a viscosity increasing agent, and advantageously small amounts of both a polymeric emulsifier and an oil component. The topical compositions of the present invention are tolerated exceptionally well by subjects to whom the compositions are administered.

Topical pharmaceutical compositions for treating skin conditions

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.

Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Topical dapsone and dapsone/adaplene compositions and methods for use thereof

Stabilized efinaconazole formulations

In one aspect, topical pharmaceutical compositions for treating a skin condition or disorder are provided. In some embodiments, the topical pharmaceutical composition is formulated as a lotion and comprises a therapeutically effective amount of an active agent; a viscosity increasing agent; a polymeric emulsifier; and an oil component. In some embodiments, the topical pharmaceutical composition comprises tretinoin.

Topical pharmaceutical compositions comprise a combination of a corticosteroid and a retinoid; and methods for treating psoriasis with same. In one embodiment, the corticosteroid comprises halobetasol propionate, and the retinoid comprises tazarotene.

Growing community of inventors

San Francisco, CA, United States of America

Varsha D Bhatt